Revisions for DENIS Study | Registro Público Cubano de Ensayos Clínicos

Comparing two revisions:

--- 15 February 2019 - 4:39pm by CIGB
+++ 3 May 2022 - 10:59am by CIGB
-/10/22
+/02/15
-/10/22
+/02/15

Revision of 3 May 2022 - 10:59am:

DENIS Study

General information

Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.

Scientific title:

Recombinant streptokinase in the treatment of complex complicated parapneumonic pleural effusion in pediatrics

Secondary indentifying numbers:

IG/CIGB-SK/DP/1701

Issuing authority of the secondary identifying numbers:

Provincial Pediatric Hospital "Dr. Eduardo Agramonte Piña ", Camaguey.

Source(s) of monetary or material support:

Center for Genetic Engineering and Biotechnology (CIGB), Havana. Ministry of Public Health, CUBA.

Authorization for beginning

Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.

Regulatory instance to authorize the initiation of the study:

Only approved by Ethics Committees

Principal investigator

Section to complete information about Email address, telephone number and postal address of the Principal Investigator.

First name:

Yanet

Midle name:

de los Angeles

Last name:

Loret de Mola Bueno

Medical Specialty :

2nd Degree Specialist in Intensive Therapy and Emergency

Affiliation:

Provincial Pediatric Hospital "Dr. Eduardo Agramonte Pinna"

Postal address:

Dolores Betancourt No 2 entre Domingo Puentes y Carretera de Santa Cruz

City:

Camaguey

Country:

Cuba

Zip Code:

10700

Telephone:

+53-32282014

Email address:

loret.cmw@infomed.sld.cu

Clinical sites to participate

Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.

Countries of recruitment:

Cuba

Clinical sites:

Not applicable

Research ethics committees:

Provincial Pediatric Hospital "Dr. Eduardo Agramonte Piña ", December 19, 2017.

Recruitment status

Section to complete information about the recruitment status and the date of first enrolment subject

Recruitment status:

Recruiting

Date of first enrollment:

17/09/2018

Health condition and Intervention

Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).

Health condition(s) or Problem(s) studied:

Complicated parapneumonic pleural effusion

Health condition(s) code:

Pleural Effusion

Pleural Diseases

Respiratory Tract Diseases

Intervention(s):

Group I (Experimental): Intravenous antibiotic therapy (according to unit protocol, pleural puncture and placement of chest drainage under local anesthesia and sedation, and assisted video-assisted thoracoscopy in cases that require it) + thrombolytic therapy with Heberkinasa (recombinant streptokinase, a daily intrapleural administration of 200 000 IU of rSK for 3-5 days). Group II (Control): Intravenous antibiotic therapy (according to unit protocol, pleural puncture and placement of chest drainage under local anesthesia and sedation, and assisted video-assisted thoracoscopy in cases that require it).

Intervention code:

Streptokinase

Thrombolytic Therapy

Antibiotic Prophylaxis

Punctures

Drainage

Thoracoscopy

Thoracic Surgery, Video-Assisted

Administration, Intravenous

Intervention keyword:

Intrapleural administration

Outcomes and Timepoint

Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.

Primary outcome(s):

1) Resolution of pleural effusion at the end of treatment (Yes, No, and time [in days]) checked by chest x-ray and chest ultrasound. 2) Need for surgical treatment (assisted video-assisted thoracoscopy - VATS, thoracotomy with decortication), (Yes, No) due to failure of conventional or experimental therapy (SKr).

Key secondary outcomes:

1) Time to extract the drainage (in days, time from the insertion of the drainage to the extraction of the drainage, by resolution of the pleural effusion verified by ultrasound and chest x-ray in the anteroposterior position). Measurement time: daily until drain extraction. 2) Stay in intensive care: given by the time (in days) from the inclusion of the patient in the study and insertion of chest drainage until discharge from intensive therapy. Measurement time: daily until discharge in intensive therapy. 3) Evolution (disappearance or improvement) of the main symptoms and signs related to the health problem under investigation, present at the time of the patient's inclusion in the study, measured by anamnesis (following the same criteria of intensity used to evaluate the events adverse [mild, moderate or severe]), physical examination, etc. Measurement time: daily during intensive therapy admission. 4) Need (Yes, No) and time (in days) of ventilatory support or non-invasive ventilation after the intervention in patients not ventilated at the time of inclusion in the study. To enter the clinical trial with some ventilatory support, the time that required it (days) will be measured. Measurement time: daily during intensive therapy admission. 5) Mortality (Yes, No). Measurement time: during the hospital stay. 6) Safety measured through the occurrence of clinical adverse events (Occurrence of AE (Yes, No) Description of AE (name of event) Intensity of AE (mild, moderate, severe) Causality (Not related, Doubtful, Possible, Probable, Definitive) Result (Completely resolved, Resolved with sequelae, Conditions in improvement, Present and unchanged condition, Worsening, Death caused by this event) Measurement time: Daily until hospital discharge.

Selection criterias

Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.

Gender:

Male/Female

Minimum age:

1 year

Maximum age:

18 years

Inclusion criteria:

1) Patients of any sex, with ages between 1 and 18 years. 2) Patients diagnosed with complicated complicated parapneumonic pleural effusion, who meet any of these clinical criteria: a) Complex pleural effusion, with septa, partitions or particles in suspension in the chest ultrasound that persists after 12 hours of placement of the pleural drainage. b) Fibrin finding in the chest drainage placement procedure. c) Appearance of septa, septa or fibrin within 10 days after drainage is placed. 3) Voluntariness of the parents or guardians of the patient, by signing the informed consent.

Exclusion criteria:

1) Post-operative of recent major surgery (first 48 hours). 2) Presence of bronchopleural fistula. 3) Active bleeding or blood dyscrasias or arteriovenous or aneurysmal malformations. 4) Patient with intracranial tumor or stroke. 5) Patients with endocarditis or with a history of heart disease. 6) Unstable or catecholamine resistant septic shock, multiple organ failure. 7) Treatment with KS in the last six months. 8) Patients with some risk condition of major bleeding (contraindications established for intravenous KS). 9) Decompensated chronic disease: diabetes mellitus, heart failure, hypertension, among others. 10) Pregnant or lactating patients at the time of inclusion in the study. 11) Patients with allergies to SK or any ingredient of the formulation.

Type of population:

Children

Type of participant:

Patients

Study design

Section to complete information about the characteristics of the study design.

Type study:

Interventional

Purpose:

Treatment

Allocation:

Randomized controlled trial

Masking:

Open

Control group:

Active

Study design:

Parallel

Phase:

4

Target sample size:

60

Contact for public queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status

First Name:

Francisco

Last Name:

Hernández Bernal

Specialty:

Doctor of Medical Sciences, 2nd grade specialist in Hygiene and Epidemiology.

Affiliation:

Center for Genetic Engineering and Biotechnology (CIGB).

Postal Address:

Ave. 31 entre 158 y 190, Cubanacan, Playa.

City:

La Habana

Country:

Cuba

Zip Code:

6162

Telephone:

+537-2085887, +537-2087465

Email :

hernandez.bernal@cigb.edu.cu

Contact for scientific queries

Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.

First Name:

Yanet

Middle Name:

de los Ángeles

Last Name:

Loret de Mola Bueno

Specialty:

2nd grade specialist in Intensive and Emergency Therapy

Affiliation:

Provincial Pediatric Hospital "Dr. Eduardo Agramonte Piña"

Postal Address:

Dolores Betancourt No 2 entre Domingo Puentes y Carretera de Santa Cruz

City:

Camaguey

Country:

Cuba

Zip Code:

10700

Telephone:

+53-32282014

Email :

loret.cmw@infomed.sld.cu

About study completion

Section to complete the data related to the study completion.

Final enrolment number:

12

Registration and Update

Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).

Primary registry:

RPCEC

Unique ID number:

RPCEC00000292

Date of Registration in Primary Registry:

22/10/2018

Record Verification Date:

2019/02/15

Next update date:

2020/02/15

Link to the spanish version:

Click here

Registered Trials

Registration process

DENIS Study

About the RPCEC

Useful resources